Trial Profile

A Pilot, Phase II, Open-Label, Single Arm Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GW640385 When Administered With Ritonavir in Combination With NRTIs for 48 Weeks in HIV-1 Infected Adults.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brecanavir (Primary) ; Nucleoside reverse transcriptase inhibitors; Ritonavir
Indications HIV-1 infections
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use

03 Apr 2013 Company changed from GlaxoSmithKline to ViiV Healthcare as reported by ClinicalTrials.gov.
31 Mar 2009 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com